Life insurance applicants increasingly using longevity drugs, warns Swiss Re

Repurposed drugs used for longevity are gaining popularity, according to global reinsurance group Swiss Re, prompting it to introduce guidance for underwriters on how to assess life insurance applicants who show signs of their use.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Elliot Field at efield@newtonmedia.co.uk or Adrian Tapping at atapping@newtonmedia.co.uk

Hannover Re blames loss of contract for bumpy 1/7 renewals

Howden slashes borrowing costs by $8m in tight debt deal

Chubb backs in-house veterans to power surety and North America growth

CEO exits trigger leadership reshuffle at Lancashire and Lloyd’s syndicate

Subsidence claims spike as UK records warmest spring on record

Lockton shuffles US national leadership for focussed client needs

Markel heads ‘down under’, taps Tokio Marine Kiln head of marine

Huge gaps in cat model implementation: Aon survey

Life insurance applicants increasingly using longevity drugs, warns Swiss Re

Editor's picks

Editor's picks

More articles